CASI Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (22 Apr 2024 @ 16:00):

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally...

Stats
Today's Volume	12 303.00
Average Volume	207 700
Market Cap	32.57M
EPS	$0 ( 2024-04-01 )
Next earnings date	( $-0.0500 ) 2024-05-15
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.200
ATR14	$0.0460 (1.87%)

Insider Trading

Date	Person	Action	Amount	type
2022-09-07	Zukiwski Alexander A	Buy	3 000	Employee Stock Option (Right to Buy)
2022-09-06	Huang James	Buy	33 300	Common Stock
2022-08-31	Huang James	Buy	400	Common Stock
2022-08-24	Huang James	Buy	39 527	Common Stock
2022-08-19	Huang James	Buy	40 000	Common Stock

INSIDER POWER
100.00
Last 95 transactions
Buy: 27 815 562 \| Sell: 9 916 643

CASI Pharmaceuticals Inc Correlation

10 Most Positive Correlations
CLXT	0.925
MBIO	0.909
HBIO	0.898
TLSA	0.895
SONM	0.886
KC	0.884
ACACU	0.878
BMEA	0.873
CREX	0.871
DFPH	0.869

10 Most Negative Correlations
ATHN	-0.923
SBNY	-0.91
CTAC	-0.9
CMLT	-0.9
KURI	-0.889
ITAC	-0.883
GLADL	-0.882
GCAC	-0.879
MCAE	-0.872
SRAC	-0.858

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

CASI Pharmaceuticals Inc Financials

Annual	2023
Revenue:	$33.88M
Gross Profit:	$18.98M (56.03 %)
EPS:	$-2.02

Q4	2023
Revenue:	$6.09M
Gross Profit:	$3.82M (62.70 %)
EPS:	$-0.450

Q3	2023
Revenue:	$8.84M
Gross Profit:	$5.19M (58.72 %)
EPS:	$-0.350

Q2	2023
Revenue:	$9.82M
Gross Profit:	$5.83M (59.41 %)
EPS:	$-0.770

Financial Reports:

No articles found.

CASI Pharmaceuticals Inc

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase I/IIa trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome. Its product pipeline also comprises CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; and Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors. The company has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland.